A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
ConditionHealthy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-55
SponsorMerck Sharp & Dohme LLC
About this trial
The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Eligibility criteria
Qualifiers
Is in good health before randomization
Has a body mass index (BMI) ≥18 and ≤32 kg/m², inclusive
Disqualifiers
Has a history or presence of clinically significant medical or psychiatric condition or disease
Has a history of cancer
Trial design
Treatments tested in this trial
- MK-7262
- Enlicitide
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov